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Abstract
The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in
relapsing–remitting multiple sclerosis (RRMS). The objective of this study was to evaluate up to 15 years of GA as a sole
disease-modifying therapy. Two hundred and thirty-two patients received at least one GA dose since study initiation in
1991 (mITT cohort), and 100 (43%, Ongoing cohort) continued as of February 2008. Patients were evaluated every
6 months using the Expanded Disability Status Scale (EDSS). Mean GA exposures were 8.6 5.2, 4.81 3.69, and
13.6 1.3 years and mean disease durations were 17, 13, and 22 years for mITT, Withdrawn and Ongoing cohorts,
respectively. For Ongoing patients, annual relapse rates (ARRs) maintained a decline from 1.12 0.82 at baseline to
0.25 0.34 per year; 57% had stable/improved EDSS scores (change 0.5 points); 65% had not transitioned to second-
ary progressive multiple sclerosis (SPMS); 38%, 18%, and 3% reached EDSS 4, 6, and 8. For all patients on GA therapy (the
mITT cohort), ARRs declined from 1.18 0.82 to 0.43 0.58 per year; 54% had stable/improved EDSS scores; 75% had
not transitioned to SPMS; 39%, 23%, and 5% reached EDSS 4, 6, and 8. In conclusion, multiple sclerosis patients with
mean disease duration of 22 years administering GA for up to 15 years had reduced relapse rates, and decreased
disability progression and transition to SPMS. There were no long-term safety issues.
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Introduction
Multiple sclerosis (MS) is a lifelong, progressive disease
and a majority of patients with relapsing–remitting
(RRMS) disease develop secondary-progressive MS
(SPMS) within two decades of diagnosis.
1,2 Therefore,
it is important to prevent accumulation of long-term
disability and slow inﬂammatory and neurodegenera-
tive MS pathology. Mechanisms related to relapse
and remission during early MS may diﬀer from those
associated with an unremitting chronic progression
of disease, and the ﬁndings of the multiple
disease-modifying therapies (DMTs) trials in SPMS
have demonstrated that they are for the most part unre-
liable in slowing the progression of disability over inter-
vals up to 3 years (glatiramer acetate [GA], Copaxone;
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3–8
As the availability of immunomodulatory therapy
for MS is relatively recent (within the last two decades),
data regarding their prospective long-term eﬀects
on disability is just beginning to be accumulated.
Follow-up assessments of patients participating in the
short-term controlled clinical trials of the interferon
beta (IFNb) drugs have found that patients continuing
to take IFNb drugs at the time of the later follow-up
visit have better neurologic status than those who
report more limited exposure to MS treatment.
9–12
Conclusions based on the ﬁndings of these studies
must be tempered by the studies’ methodological lim-
itations: importantly, data were collected after consid-
erable intervals during which patients were not
monitored and patients had frequently discontinued,
switched, or added other immunomodulators to the
IFNb drug under study.
Two recent prospective non-randomized open-label
studies have attempted to assess the continuous use of
DMTs for 7–8 years. Trojano et al.
13 evaluated the
eﬀects of DMT use over 7 years of follow-up and
Brown et al.
14 over 25 years of follow-up (the DMT
treatment period in the latter study was up to
8.4 years). Although caution must be used in evaluating
the results of these studies due to the uncontrolled
nature of open-label studies, the ﬁndings of these stu-
dies suggest that, as a group, DMTs delayed accumu-
lation of disability in RRMS patients as measured by
Expanded Disability Status Scale (EDSS) scores and
conversion to SPMS compared with no treatment.
The ongoing US Glatiramer Acetate Trial is unique
in that it is an open-label study that prospectively and
regularly evaluates patients with RRMS on continuous
therapy with a single immunomodulating agent for an
extended period of time. Now at the 15th year of the
study, patients ongoing in the study have an average of
13.6 years of GA treatment. Beginning in 1991, 251
RRMS patients enrolled in the multicenter
placebo-controlled double-blind US pivotal trial. At
the end of the double-blind placebo-controlled phase,
placebo patients were crossed over to GA and the pro-
spective open-label study was begun. The clinical eﬀec-
tiveness and safety of GA in this study have been
reported at 2 and 3 years compared with placebo,
15,16
and at 6, 8, and 10 years in the open-label study.
17–19
This report further describes the long-term eﬃcacy
and safety of daily GA in carefully monitored patients
who have received continuous GA as their sole DMT,
beginning as early as 1991.
Methods
Patients
The patients with RRMS who have participated in this
trial have been described previously.
19 Brieﬂy, patients
who participated in the double-blind placebo controlled
pivotal trial were asked to enroll in the open-label
extension phase (Figure 1). Patients originally rando-
mized to active treatment continued to take daily GA
and those randomized to placebo switched to GA
20mg/day SC. The modiﬁed intention-to-treat (mITT)
population reported here diﬀers from the original ITT
EDSS assessment
Ongoing
mITT
(n=232) 8.6 years
13.6 years
n=100
n=131
15 year analysis
Withdrawn
4.8 years
Months
Open-label extension phase
Glatirarner acetate
Placebo
0 35+ 60
50 patients
returned for LTFU
180 120+
Double - blind,
placebo - controlled
phase
Continuous GA treatment
EDSS assessed every and months 3 6 9 1215182124273033
Figure 1. Study design for the long-term glatiramer acetate (GA) study of patients who participated in the placebo-controlled study
and were entered into the open-label study of GA. Patients on placebo in the placebo-controlled phase were switched to active
treatment with GA in the open-label phase and those on GA in the placebo-controlled phase continued on it. The mean number of
years of GA treatment for the Ongoing cohort was 13.6 years, for the mITT cohort was 8.6 years and for the Withdrawn cohort was
4.8 years.
Ford et al. 343cohort (n¼251) of the pivotal trial in that the mITT
cohort includes only patients who have received at least
one dose of GA (19 patients initially randomized to
placebo in the pivotal study did not participate in the
open-label extension and are excluded from the mITT
cohort). The mITT population is sub-divided into two
patient cohorts, the Ongoing cohort, who are patients
that continued in the study as of February 2008, and
the Withdrawn cohort, who are patients that withdrew
from the study at some point after starting GA therapy.
At the time of data cut-oﬀ for this analysis, February
2008, 100 patients continued in the ongoing study
(Ongoing cohort). Patients who had received GA
from randomization had been treated for up to 15
years and patients originally randomized to placebo
had been receiving GA for up to 13 years.
Study design
The US Glatiramer Acetate Pivotal Trial, a
double-blind, randomized, placebo-controlled study,
was initiated in October 1991. All of the 11 original
US academic centers continue to participate, and the
Institutional Review Boards at all centers continue to
approve participation in the study.
Neurological status is evaluated in the clinic every
6 months by EDSS. Patients are examined within
7 days if they experience symptoms suggestive of a
relapse (appearance or reappearance of one or more
neurologic abnormalities persisting for at least
48 hours, preceded by a stable or improving neurological
state of at least 30 days duration). During the open-label
phase, laboratory assessments (chemistry panel) and
vital signs are documented at 6-month study visits. In
most cases, patients are assessed by the same neurolo-
gists and study coordinators at each visit.
Any patient who discontinued daily GA for any
reason, or who took another immunomodulator, was
withdrawn from the study. Thus, while in the study,
these RRMS patients received only continuous GA
monotherapy for disease modiﬁcation. Reasons for
withdrawal were classiﬁed into three categories: (1) with-
drawal due to adverse events, (2) lost-to-followup, and
(3) withdrawal due to ‘patient decision’ or ‘other’. The
reasons under the patient decision/other category were
further divided into subcategories to gain a better under-
standing of why patients discontinued the study.
Fifteen-year analyses
Demographic characteristics were collected for the year
prior to patients starting GA therapy. Time of ‘disease
onset’ was deﬁned as the time patients experienced their
ﬁrst MS symptom (reported by patients at study entry).
Changes in disability were measured by mean yearly
EDSS scores and mean changes in EDSS from GA
start to the last observation while on GA in the mITT,
Ongoing, and Withdrawn patient cohorts. EDSS at GA
start was the EDSS score of the patient when they began
GA therapy (i.e. at randomization for patients originally
randomized to GA, and at entry into the open-label
extension study for patients who were initially rando-
mized to placebo). Categorical analyses of patients’ neu-
rological status were performed; patients were classiﬁed
as ‘stable/improved’ if EDSS scores were changed by
 0.5 EDSS points, did not change, or decreased from
onset of treatment; ‘worsened’ status was used to
describe increases of more than 0.5 EDSS points.
Proportions of patients who reached conﬁrmed
scores of EDSS 4, 6, or 8 while on GA and time to
these EDSS thresholds were obtained for the mITT,
Ongoing, and Withdrawn cohorts (only patients who
began GA therapy with EDSS scores lower than the
EDSS threshold were included in these analyses).
Categorical analyses and proportions of patients
who reached predeﬁned EDSS thresholds (EDSS 4, 6,
and 8) were also measured in patients of the mITT
cohort stratiﬁed by EDSS score at GA start. The
Low EDSS strata consisted of patients with EDSS 0
to 2.0 at GA start and the High EDSS strata included
patients with EDSS  2.5 at GA start.
Deﬁnitions of conﬁrmed progression to SPMS vary
among neurologists and within the literature, since it is
diﬃcult to accurately determine the onset of chronic
progression, even in patients who are evaluated fre-
quently.
9,10,20 In this study, SPMS was deﬁned as an
increase of >1.0 EDSS point sustained for 12 months,
without relapses occurring during that period.
The annualized relapse rate (ARR) was calculated
for each patient by dividing the total number of
relapses by the number of years of exposure to GA.
Statistical methods
Propensity score analyses. As the study has been run-
ning continuously for more than 15 years, there was con-
cern that there might be a treatment bias between the
Withdrawn and Ongoing cohorts due to either their
demographic characteristics at GA start or their initial
randomization into a GA or placebo treatment group in
the original double-blind study. A propensity score is a
statistical method
21,22 that can be used to partly adjust
for bias of baseline characteristics between the ongoing
and the withdrawal cohorts, by equating these subgroups
according to these covariates. The propensity scores were
constructed for each patient using a logistic regression
ﬁtted to the data with the cohort (either Ongoing or
Withdrawn) as the dependent variable and the following
as independent variables: age at disease onset, age at GA
start, gender, disease duration, relapses 2 years prior,
344 Multiple Sclerosis 16(3)EDSS, and randomization grouping. A stepwise algo-
rithm was used to ﬁnd the most explanatory variables
from the above-stated characteristics, second-order inter-
actions and third-order interactions.
Analyses of clinical endpoints. Descriptive statistics are
reported for changes from GA start in ARR, changes
from GA start in EDSS scores, and yearly EDSS
scores. Kaplan–Meier survival methods were used to esti-
mate the median time to EDSS 4, 6, and 8 while on GA.
Chi-squared analyses were used for binary variables (the
proportion of patients reaching EDSS scores 4, 6, and 8)
and t-tests were used for continuous variables (last EDSS
score while on GA and change from GA start to last
EDSS); and to compare the outcomes between stratiﬁed
patients with EDSS scores 0–2 and those with EDSS
scores  2 . 5a tG As t a r t .T h ep e r c e n to fm I T T ,
Ongoing, and Withdrawn patients who transitioned to
SPMS over the course of the study are reported.
Results
Patients
A total of 232 patients who had received at least one
dose of GA since study inception comprised the mITT
cohort. One patient discontinued after receiving GA but
before undergoing neurological evaluation; therefore,
theeﬃcacyevaluablemITTcohortincluded231patients.
As of February 2008, 100 out of the 232 patients (43%)
remained in the study and comprised the Ongoing
cohort. The Withdrawn cohort consisted of 131 patients.
Propensity scores. The descriptive statistics for the
patient characteristics used as independent variables
in the propensity score analyses are presented in
Table 1. There were no signiﬁcant diﬀerences between
the Ongoing and Withdrawn cohorts for patient char-
acteristics except for EDSS at GA start (t-test,
p¼0.0053). There were no signiﬁcant diﬀerences in
the percentage of patients in the Ongoing or
Withdrawn cohorts due to their original randomization
group (chi-squared test, p¼0.3022). For the Ongoing
cohort, 50 patients were randomized to GA (50%) and
50 patients were randomized to placebo (50%). For the
Withdrawn cohort, 75 patients were randomized to GA
(57%) and 57 were randomized to placebo (43%,
p¼0.3522). The ﬁnal model following the implementa-
tion of the logistic regression model included the fol-
lowing variables: EDSS at GA start, age at GA start,
gender and the interaction between age at GA start and
gender. There were no diﬀerences in the cohorts’ pro-
pensity scores (mITT mean score¼0.43 0.12,
Ongoing¼0.47 0.12 and Withdrawn¼0.40 0.12).
This indicates that there was a similar distribution of
their patient characteristics at GA start and therefore it
was not appropriate to adjust the subsequent analyses
of the clinical endpoints using the propensity scores.
Stratification by EDSS scores at GA start. Patients of
the mITT cohort stratiﬁed by EDSS score at GA start
included 103 patients in the Low EDSS (0–2.0) stratum
and 129 patients in the High ( 2.5) EDSS stratum. At
GA start, mean SD and range of EDSS scores in the
mITT were 1.5 0.6 (range: 0–2.0) in the Low strata,
and 3.9 1.1 (range: 2.5–7.0) in the High strata.
Patients in the High EDSS strata at GA start tended
to be slightly older than those in the Low EDSS strata
(36.4 6.4 years versus 34.7 6.1 years, respectively)
and to have longer mean disease duration at study
start (9.0 5.4 years versus 7.3 4.7 years, respectively).
Patient discontinuation. Eight patients left the study
since the previously reported patient follow-up in
November 2003.
19 The reasons for withdrawal at the
termination visit were categorized by the study sites as
patient decision. Reasons included: increase in relapses
(n¼1), progression of disability (n¼1), patient believes
they have benign MS (n¼1), tired of traveling to inves-
tigative site (n¼1), and want to try another immuno-
modulator (n¼4; three natalizumab and one
interferon-b-1a SC). Discontinuation reasons for all
patients (n¼132) who have left the trial since 1991
are listed in Table 2.
Table 1. Patient characteristics at glatiramer acetate start
Characteristic
mITT cohort
n¼232
Ongoing cohort
n¼100
Withdrawn cohort
n¼132
Age at multiple sclerosis disease onset (mean SD) 27.40 6.18 28.06 6.31 26.90 6.05
Age (mean SD) 35.5 6.4 35.1 5.8 33.8 6.5
Gender (% female) 73% 70% 76%
Mean relapse rate 12 months before GA start 1.18 0.82 1.12 0.82 1.23 0.83
Expanded Disability Status Scale score (mean SD) 2.8 1.50 2.5 1.3 3.0 1.6
Disease duration (years, mean SD) 8.3 5.12 8.4 5.14 8.13 5.12
GA, glatiramer acetate.
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At the time of the 15-year analysis, the mean disease
duration from disease onset was 22.0 years for the
Ongoing cohort, and for the total mITT cohort and
the Withdrawn cohort while in the study was 17 and 13
years, respectively. All Ongoing patients had completed
the 15-year clinical visit of the study; however, the
patients in the Ongoing cohort who were switched
from placebo to GA therapy at the end of the
placebo-controlled trial (n¼50) had a GA exposure of
12.3 0.10 years (range: 11.7–12.5) and those who
started GA at randomization (n¼50) have a mean GA
exposure of 14.9 0.10 years (range: 14.6–15.3). Thus,
the mean ( SD) number of GA treatment years for the
Ongoing cohort was 13.6 1.3 (range: 11.7–15.3) years.
The mean number of GA treatment years was 8.6 5.2
(range: 0.2–15.3) for the mITT cohort, and 4.8 3.7
(range: 0.2–14.2) years in the Withdrawn cohort. Mean
( SD) and median ages of the Ongoing cohort were
50 5.9 years and 49.9 years. Mean ( SD) and
median ages for the mITT cohort were 44.2 8.4 years
and 45.1 years, for the Withdrawn cohort, 33.8 6.5
years and 34.5 years. The ARR in the Ongoing Cohort
declined from 1.12 0.82 before starting GA therapy to
0.25 0.34 at the 15-year analysis. The change in ARR
from GA start to the last observed value on GA therapy
in the study for the mITT cohort declined from
1.18 0.82 to 0.43 0.58 and for the Withdrawn
cohort from 1.23 0.83 to 0.56 0.68.
Changes in mean EDSS scores from GA start to last
observation while on GA were 0.96 1.8, 0.6 2.0, and
1.0 1.7 for the mITT, Ongoing, and Withdrawn
cohorts (Table 3). Yearly mean ( SE) EDSS scores
for the Ongoing patients are shown in Figure 2.
Overall, 54% of the mITT, 57% of the Ongoing
Table 3. Changes in Expanded Disability Status Scale from glatiramer acetate start to the
last observation while on glatiramer acetate for the 15-year analysis
While on GA
mITT cohort
n¼231
Ongoing cohort
n¼100
Withdrawn cohort
n¼131
Time from GA start to last observation (years)
Mean SD 5.59 5.23 13.57 1.32 4.81 3.69
Median 9.94 13.56 3.79
Range 0.18–15.30 11.68–15.30 0.18–14.19
EDSS score at GA start
Mean SD 2.8 1.5 2.5 1.3 3.0 1.6
Median 2.5 2.2 3.0
Range 0–7.0 0–6.0 0.0–7.0
EDSS at last observation
Mean SD 3.6 2.2 3.1 2.1 4.0 2.3
Median 3.5 2.8 3.5
Range 0–9.0 0–8.5 0.0–9.0
EDSS change from GA start to last observation
Mean SD 0.9 1.8 0.6 2.0 1.0 1.7
Median 0.5 0.5 0.5
Range  3.5–6.5  3.5–6.5  3.5–5.5
Average EDSS change per year
Mean SD 0.2+ 0.6 0.1+ 0.2 0.5+ 0.8
Median 0.1 0.0 0.3
Range  1.8–4.0  0.3–0.5  1.8–4.0
EDSS, Expanded Disability Status Scale; GA, glatiramer acetate.
Table 2. Reasons for patient withdrawal
Reason for
withdrawal n
Patient
decision/other
subcategories* n
Total 132 Total 95
Lost to follow-up 14 Patient perception
of disease worsening
29
Adverse event 23 Desire to switch
or combine therapies
26
Patient decision/other 95 Difficulty, inability, or
unwillingness to adhere
to study protocol
32
Pregnancy 8
*Patient decision/other subcategories were derived from written com-
ments provided by Withdrawn patients at their final visit.
346 Multiple Sclerosis 16(3)cohort and 52% of the Withdrawn cohort while on GA
had stable/improved EDSS scores. Statistics of mITT,
Ongoing, and Withdrawn patients who progressed to
SPMS while in the study are shown in Table 4.
Twenty-ﬁve percent of the mITT cohort and 17% of
the Withdrawn patients reached SPMS while on GA
and 35% of the Ongoing cohort have converted to
SPMS at the time of the 15-year analyses.
The proportions of patients reaching deﬁned EDSS
thresholds of 4, 6, and 8, while on GA therapy, are
39%, 23%, and 5% for mITT; 38%, 18%, and 3%
for ongoing; and 40%, 27%, and 6% for withdrawn
patients, respectively. The duration of follow-up for
the mITT cohort was 5.6 years, the Ongoing cohort
13.6 years, and the Withdrawn cohort 4.8 years. The
median times to EDSS 4, 6, and 8 were not reached
(i.e. 50% of the cohort did not reach the endpoint).
The estimated time for one quartile (25%) of patients
to reach EDSS 4 was 4.0 years in the mITT cohort, 6.8
years in the Ongoing cohort, and 2.75 years in the
Withdrawn cohort. The estimated time for one quartile
(25%) of patients to reach EDSS 6 was 3.9 years for the
Withdrawn cohort. Less than 25% of the mITT and
Ongoing cohorts reached EDSS 6, and less than 25%
of any cohort reached EDSS 8 by year 15 of the trial
(Figure 3).
Low versus High EDSS strata. There were no signiﬁ-
cant diﬀerences between the baseline Low and High
EDSS strata in the proportion of patients with stable/
improved EDSS scores at the 15-year analysis in the
mITT cohort (54.4% versus 54.3%, respectively).
There were signiﬁcant diﬀerences in the proportion of
patients in the Low and High strata of the mITT cohort
reaching EDSS thresholds of 4, 6, and 8 (Figure 4). In
the Low stratum of the mITT cohort, 25%, 9% and 1%
reached EDSS thresholds of 4, 6, and 8, respectively,
and in the High EDSS stratum, 61%, 34%, and 8%
reached EDSS 4, 6, and 8, respectively.
Safety
The most commonly reported adverse events in patients
receiving long-term GA, regardless of whether the
investigator judged them to be related to GA therapy
or not, were accidental injury, muscle weakness, back
pain, dizziness, depression, hypoesthesia, paresthesia,
insomnia, upper respiratory infections and urinary
tract infections, headache, and pain. Adverse events
thought to be related to GA therapy were consistent
with known side eﬀects of GA administration and
included local injection-site reactions (e.g. erythema,
pain, nodules, edema) and symptoms associated with
an immediate post-injection reaction (IPIR), which
may have included vasodilation, chest pain, palpitation,
tachycardia, or dyspnea. No apparent time-dependent
Table 4. Progression to secondary-progressive multiple sclerosis
While on GA
Number
of patients
progressed
to SPMS (%)*
EDSS
Mean  SD
Median
Disease duration
GA start (years)
Mean SD
Median
Disease duration
total (years)
Mean SD
Median
Duration of
follow-up
(years on GA)
Mean SD
Median
mITT
n¼231
59 (25%)** 5.4 2.2
6.0
9.35 4.9
9.0
20.68 5.8
19.7
9.8 (3.5)
12.9
Ongoing cohort
n¼100
35 (35%) 4.9 2.2
6.0
9.82 5.0
9.0
23.3 5.1
22.3
12.0 (0.2)
12.0
Withdrawn cohort
n¼131
24 (18.3%)** 6.2 2.0
6.3
8.67 4.7
8.5
16.8 4.4
16.9
6.4 (3.4)
6.0
*Total number of patients who met the definition of SPMS, an increase of 1.0 EDSS points for 12 months with no relapses.
**Two patients in the withdrawn cohort had an increase of 1.0 EDSS points and had a relapse within the last 12 months.
GA, glatiramer acetate; EDSS, Expanded Disability Status Scale; SPMS, secondary-progressive multiple sclerosis.
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Figure 2. Yearly mean Expanded Disability Status Scale (EDSS)
scores for Ongoing patients (n¼100) in the glatiramer acetate
(GA) study at the 15-year analysis. The asterisk (*) indicates that
the yearly mean EDSS scores for years 14 and 15 are derived
from the scores of patients who were originally randomized to
GA in the placebo-controlled phase of the study (n¼50).
Ford et al. 347adverse events emerged. No evidence of hematologic,
hepatic, or renal dysfunction; immunosuppression;
emergence of malignancy; or development of other
autoimmune disease was observed. There was one
death due to respiratory failure caused by pneumonia
that was not believed to be drug related.
Discussion
Results of this prospective, ongoing, open-label study
indicate that long-term continuous GA use is safe and
that the majority of the patients continuing on GA ther-
apy in the study have had few relapses and minimal
disease progression. With a mean disease duration of
22 years and mean patient age of 50 years, two-thirds
of patients receiving continuous GA as sole
immunomodulatory therapy for 15 years have not tran-
sitioned to SPMS, 57% have retained stable or improved
EDSS scores over the course of the study, and 82%
remain ambulatory without mobility aids. No unfore-
seen adverse events to GA therapy occurred.
While receiving GA, the Withdrawn cohort, which
included all patients who received at least one GA dose
and subsequently left the study, and the Ongoing cohort
patients appeared to do comparably well; however, it is
important to remember that the mean disease durations
in these cohorts were diﬀerent (13 versus 22 years, respec-
tively). Outcomes in the Withdrawn cohort reﬂect the last
observed value carried forward, and patients who left the
trial may have done so at any stage in their disease
course. Although patients withdrew for many stated rea-
sons, a signiﬁcant proportion did so because they may
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Figure 3. Time to reach confirmed Expanded Disability Status Scale 4, 6, and 8 for the mITTand Ongoing cohorts while they were
on glatiramer acetate therapy. The mean disease duration at glatiramer acetate start for the mITT cohort was 8.3 years and for the
Ongoing cohort was 8.4 years.
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Figure 4. Proportion of Low and High strata mITT patients reaching Expanded Disability Status Scale (EDSS) 4, 6, and 8. The
proportion of patients in the Low and High strata mITT cohorts reaching the EDSS thresholds of EDSS 4, 6, and 8 was significantly
different (*p<0.02). Patients in the Low strata had EDSS scores of 0–2.0 at glatiramer acetate (GA) start (n¼103) and those in the
High strata had EDSS scores  2.5 at GA start (n¼129).
348 Multiple Sclerosis 16(3)have had more signiﬁcant progression of clinical disabil-
ity than those who stayed in the study. Approximately
41% of all patients who withdrew from the study indi-
cated that they perceived that their disease was progress-
ing or that they wanted to switch treatments. Of the
withdrawal patients, those who progressed to SPMS
had a mean EDSS of 6.2 with disease duration of 17
years. No follow-up neurologic assessment has been per-
formed on the eight patients who have left the study since
the 2003 assessment.
19
Our results are prospective and should not be com-
pared directly with those of recent, retrospective inves-
tigations on the beneﬁts of long-term DMT use. In
other long-term follow-up studies, patient assessments
have been relatively infrequent, patient populations are
diﬀerent or less well deﬁned, disease durations and
follow-up intervals vary, subjects are not on a single
drug and the studies use diverse methodologies and
deﬁnitions for data collection and reporting. This
open-label prospective extension study of GA as
single immunomodulatory therapy, with highly con-
trolled, consistent follow-up, is the only long-term
study in MS in which patients were required to
remain on a single immunomodulator and not switch
or add concomitant immunotherapy. The long-term
extension studies of IFNb-1b (16-year follow-up visit)
and IFNb-1a SC (PRISMS 8-year follow-up visit)
included time periods in which patients may have
used other immunomodulatory therapy or none at all.
In the 16-year follow-up study of IFNb-1b, the mean
time since diagnosis in the long-term follow-up (LTFU)
cohort (260/372, 70%) was 20 years.
23,24 Of patients
who received IFNb-1b for more than 80% of the
16-year interval, approximately 44% reached EDSS
 6 and 29% reached EDSS 8. The estimated median
time to EDSS 6 in those patients was approximately
13 years.
24 For those patients on IFNb-1b for less
than 10% and between 10% and 80% of the 16-year
interval, 44% and 31% reached EDSS 8, respectively.
In the current study, only 18% of Ongoing patients,
with slightly longer disease duration (22 years), reached
EDSS 6 and 3% reached EDSS 8 while on GA. In
addition, the proportion of patients who were judged
to have converted to SPMS in the IFNb-1b study was
45% versus 35% of Ongoing patients and 25% of
mITT patients in this GA study.
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In the 7- to 8-year follow-up to the PRISMS study of
IFNb-1aSC,382outof560patientsreturnedforasingle
follow-up assessment (approximately 13 years from dis-
ease diagnosis for the ITT population).
9 Of the original
PRISMS ITT cohort, 20% (110/557) had reached EDSS
 6 (regardless of treatment), roughly the same propor-
tion of Ongoing patients in the current study who had a
disease duration of 22 years. In PRISMS LTFU
patients, mean increase from baseline EDSS score at
8yearsfromstudystartwas1.1pointandapproximately
60% of patients had a 1.0-point EDSS progression. In
the current study, Ongoing patients had a mean increase
of 0.6 EDSS points at the 15-year follow-up and 57%
had progressed  0.5 EDSS points.
In long-term studies such as this, there are inherent
limitations that make it inappropriate to draw deﬁnitive
conclusions about the clinical eﬃcacy of a therapy.
Weaknesses of the current study include lack of a con-
current randomized control group and the potential for
selection bias when patients with more aggressive dis-
ease drop out over time. At an observational level, the
results of this study show that, for the patients with
RRMS taking continuous daily GA for up to
15 years, there has been a consistent low relapse rate
and slow progression of disability. It is also possible that
these patients were destined to have relatively mild MS
and have therefore chosen to remain on the medication
longer than those with more severe disease. The reader
will need to consider the implications of these opposing
conclusions in interpreting the results presented.
The safety of GA therapy in these patients has not
changed from what has been reported previously.
15–19
The commitment of patients in the study to take daily
SC injections for 15 years underscores the long-term
tolerability and patient acceptance of GA. The study
will continue for 20 years of prospective followup.
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